| |
| |
|
|
SENATE CONCURRENT RESOLUTION
|
|
|
WHEREAS, Plaintiffs Dorena Coleman, Curtis Jackson, and |
|
|
Federico Perez, individually, (collectively referred to as |
|
|
"Plaintiffs"), filed suit on August 13, 2020, against the Texas |
|
|
Health and Human Services Commission, including employees in their |
|
|
official capacities ("HHSC"), and sought relief both on Plaintiffs' |
|
|
own behalf and on behalf of a class of similarly situated |
|
|
individuals ("Medicaid HCV Class"), and filed a motion for class |
|
|
certification on August 14, 2020; and |
|
|
WHEREAS, Plaintiffs alleged HHSC's Prior Authorization |
|
|
Criteria and Policy's use of fibrosis score as criterion for direct |
|
|
action antiviral drug (DAA) coverage violated Title XIX of the |
|
|
Social Security Act: |
|
|
(a) By discriminating among similarly situated Medicaid |
|
|
recipients on the basis of categorical restrictions that are not |
|
|
based upon prevailing clinical standards, as prohibited by 42 |
|
|
U.S.C. § 1396a(a)(10)(B)(i) and (ii) and 42 C.F.R. § 440.240; |
|
|
(b) By denying qualified Medicaid participants the |
|
|
provision of necessary medical assistance and treatment coverage |
|
|
with "reasonable promptness," as required by 42 U.S.C. § |
|
|
1396a(a)(8); |
|
|
(c) By excluding qualified Medicaid recipients from |
|
|
medically necessary treatment coverage as required by 42 U.S.C. § |
|
|
1396a(a)(10)(A); and |
|
|
WHEREAS, Defendants denied the allegations of the Lawsuit, |
|
|
denied all allegations of wrongdoing and liability, and denied any |
|
|
causation of harm or damage to the Medicaid HCV Class; and |
|
|
WHEREAS, The parties mediated this matter on December 1, |
|
|
2020, with the Honorable Patrick Keel as mediator, and thereafter |
|
|
successfully reached an agreement in principle on December 17, |
|
|
2020; and |
|
|
WHEREAS, The Parties have now agreed to a full settlement on |
|
|
the following terms: |
|
|
(a) HHSC will modify its Medicaid prior authorization (PA) |
|
|
criteria to treat chronic Hepatitis C clients who have METAVIR |
|
|
fibrosis scores of F2-F4 with Direct Acting Antiviral (DAA) |
|
|
treatment by March 1, 2021; |
|
|
(b) Between March 1, 2021, and September 1, 2021, Medicaid |
|
|
enrollees with severe extrahepatic effects of chronic Hepatitis C |
|
|
who have fibrosis scores other than F2-F4 will be approved for DAA |
|
|
treatment on a case-by-case basis by the HHSC Chief Medical |
|
|
Director or an MCO Medical Director, if they are assigned to an MCO; |
|
|
(c) As of September 1, 2021, HHSC will remove all METAVIR |
|
|
fibrosis score, drug screening, and specialist prescription PA |
|
|
criteria requirements for DAA treatment for chronic Hepatitis C |
|
|
clients, if the legislature approves the funding for HHSC's |
|
|
Exceptional Item (EI); HHSC agrees that, for the period September |
|
|
1, 2021, through August 31, 2023, HHSC will not reinstate these |
|
|
criteria; and |
|
|
WHEREAS, This Agreement is expressly conditioned upon |
|
|
approval by the Office of the Attorney General of Texas, the |
|
|
Governor of Texas, and the Texas Legislature; and |
|
|
WHEREAS, This Agreement is expressly conditioned upon |
|
|
enactment by the Texas Legislature of the EI requested by HHSC; and |
|
|
WHEREAS, Section 111.003(b), Texas Civil Practice and |
|
|
Remedies Code, requires a state agency to obtain legislative |
|
|
approval of a settlement agreement that "commits this state to a |
|
|
course of action that in reasonable probability will entail a |
|
|
continuing increased expenditure of state funds over subsequent |
|
|
state fiscal bienniums"; therefore, the Settlement Agreement is |
|
|
expressly conditioned upon the legislature approving and |
|
|
appropriating the agreed upon settlement amount; now, therefore, be |
|
|
it |
|
|
RESOLVED, That the 87th Legislature of the State of Texas |
|
|
hereby approve the proposed Settlement Agreement. |